Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

Targeted therapy with Ustekinumab significantly improved a skin condition called ILVEN, which is caused by mutations in the CARD14 gene.

The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.

Dupilumab improves skin microbiome balance in atopic dermatitis patients.

The targeted nanohybrids effectively reduced psoriasis symptoms and improved skin health.

Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.

Dupilumab effectively controls symptoms in infants with Netherton syndrome.

Wedelolactone may help treat chronic diseases due to its strong antioxidant properties.

Some elderly men had healing problems after using imiquimod and diclofenac for skin conditions on their scalps.

Dupilumab effectively treats various inflammatory skin diseases beyond its initial use for atopic dermatitis.

Albendazole can cause hair loss, and piroxicam can cause fixed drug eruption.

Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.

Patients with the same genetic mutation for vitamin D-resistant rickets showed different symptoms but all improved with treatment except for hair loss.

All four treatments for early rheumatoid arthritis had similar and mostly mild side effects.

Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.

DEC cells show promise as a safe and effective treatment for Duchenne muscular dystrophy.

Biosimilars lower costs but don't significantly improve access.

Sulfasalazine can cause severe allergic reactions leading to long-term autoimmune issues like hair loss and skin discoloration.

Apremilast improved symptoms in patients with severe skin conditions.

Methotrexate is effective for rheumatoid arthritis but can cause side effects.

Simvastatin/ezetimibe may help some patients with severe alopecia areata regrow hair.

Flammulina velutipes polysaccharide helps the immune system fight tumors by activating certain pathways.

Dimethyl fumarate speeds up wound healing in IL-36Ra deficient mice by reducing NET formation and oxidative stress.

Dupilumab effectively improves skin conditions, reduces symptoms, and enhances quality of life in certain dermatological issues.

Low-dose tofacitinib is effective and cheaper for severe alopecia areata.

The document concludes that various findings in rheumatology offer insights into disease severity, treatment responses, and potential risks in medication, with some limitations due to unspecified participant numbers.

Ruxolitinib can cause a delayed skin reaction on the nose.

GLP-1 receptor agonists can help skin conditions but may cause hair loss and other skin issues.

Deferasirox combined with sorafenib reduces liver cancer risk and lessens treatment side effects.